Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM17JSI)

Drug Name

CGC-11047 Drug Info

Synonyms

UNII-2C4Y86R2AX; 2C4Y86R2AX; (Z)-N,N'-bis[3-(ethylamino)propyl]but-2-ene-1,4-diamine; 206991-64-2; CHEMBL3104344; CGC-11047 free base; Pg-11047(free base); AC1O51NW; CHEMBL142464; SCHEMBL2360444; BDBM50445365; 308145-19-9; (Z)-N,N'-Bis[3-(ethylamino)propyl]-2-butene-1,4-diamine; 2-Butene-1,4-diamine, N1,N4-bis(3-(ethylamino)propyl)-, (2Z)-; 2-Butene-1,4-diamine, N,N'-bis(3-(ethylamino)propyl)-, (2Z)-; 2-Butene-1,4-diamine, N,N'-bis[3-(ethylamino)propyl]-, tetrahydrochloride, (2Z)-

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Phase 2	[1]

Cross-matching ID

PubChem CID: 6475492
CAS Number: CAS 308145-19-9
TTD Drug ID: DM17JSI

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Human Deoxyribonucleic acid (hDNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[3]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[4]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[5]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[6]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[7]
Carboplatin	DMG281S	Adenocarcinoma	2D40	Approved	[8]
Busulfan	DMXYJ9C	Chronic myelogenous leukaemia	2A20.0	Approved	[9]
Procarbazine	DMIK367	Hodgkin lymphoma	2B30	Approved	[10]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[11]
Dacarbazine	DMNPZL4	Adenocarcinoma	2D40	Approved	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00585416) Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer. U.S. National Institutes of Health.
2	Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047. Cancer Genomics Proteomics. 2009 May-Jun;6(3):161-75.
3	Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9.
4	Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93.
5	31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12.
6	Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.
7	O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.
8	Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
9	DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci. 2004 May;95(5):454-8.
10	Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations... DNA Repair (Amst). 2009 Jan 1;8(1):72-86.
11	Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215.
12	Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8.